Superior Boiler
Purchase-Price Allocation
Goodwill
$54.1M
2 years of history · ending 2025-12-31 · SEC EDGAR
Three classic accounting-quality scores. F-Score (0-9, higher = better fundamentals); M-Score (>-1.78 flags possible manipulation); Z-Score (>2.99 = safe, <1.81 = distressed). Use together — single-score readings are noisy.
Per-quarter consensus estimates + actuals + beat/miss surprise. Sourced from Finnhub (Wall Street consensus aggregation).
Source caveat: Finnhub free tier returns the consensus mean only — analyst high / low / dispersion + analyst counts require a paid plan. A "$5.00 consensus" line above could mean "20 analysts at exactly $5" (high conviction) or "10 at $5.50, 10 at $4.50" (split). Treat single-line consensus accordingly.
Bridges from the federal statutory rate (21% post-TCJA) to the effective tax rate via the issuer's tax-note reconciliation lines. Sourced from EffectiveIncomeTaxRateReconciliation* flat CompanyFacts concepts. Conditional lines (R&D credits, FDII, SBC, valuation allowance, etc.) only render when the issuer discloses them. Persistent divergence between accrual tax expense and cash taxes paid is a leading signal for deferred-tax buildup.
| Reconciliation Line | FY2017 | FY2018 | FY2019 | FY2025 |
|---|---|---|---|---|
| Federal Statutory Rate | 35.00% | 35.00% | 21.00% | 21.00% |
| State & Local Income Taxes | — | — | — | 3.30% |
| Foreign Rate Differential | — | — | — | 0.80% |
| Other Adjustments | — | — | — | 0.30% |
| Nondeductible Expenses | — | — | — | 0.90% |
| Valuation Allowance Change | — | — | — | -2.20% |
| Effective Tax Rate | — | — | — | 23.50% |
Cash vs Accrual
| Item | FY2017 | FY2018 | FY2019 | FY2025 |
|---|---|---|---|---|
| Income Tax Expense (Accrual) | $70.0M | $46.6M | $52.4M | $105.0M |
| Income Taxes Paid (Cash) | — | — | — | $74.4M |
Per-deal acquisition disclosures sourced from us-gaap:BusinessAcquisitionAxis dimensional XBRL. Each card surfaces the deal's purchase-price allocation (goodwill vs intangibles vs liabilities), contingent consideration (unpaid earn-outs), and pro-forma combined-entity numbers. Probability-of-Success (PoS) factor on biotech targets is the ASC 805 contingent-consideration valuation — higher = closer to commercialization, higher implied target value.
Purchase-Price Allocation
Goodwill
$54.1M
Purchase-Price Allocation
Goodwill
$41.6M
Intangibles
$2.7M
Purchase-Price Allocation
Goodwill
$35.1M
Intangibles
$39.4M
Purchase-Price Allocation
Intangibles
$2.3M
Per-category restructuring disclosures sourced from us-gaap:RestructuringCostAndReserveAxis dimensional XBRL. Negative charges indicate reversals of prior accruals (a sign the original estimate was too aggressive — flattering current-period earnings).
As of 2025-12-31
| Category | Class | P&L Charge | Cash Paid | Reserve Balance |
|---|---|---|---|---|
| Employee Severance | Employee Severance | +$18M | — | $9M |
| Facility Closing | Facility Closing | +$2M | — | — |
| Facility Closing And Other | Facility Closing | +$2M | — | $400.0K |
| Legal And Consultancy | Other | +$1M | — | $400.0K |
| Plant Write Down | Asset Impairment / Write-Down | +$900.0K | — | — |
| Other Exits Costs | Other | +$400.0K | — | — |
Phase 1: currency selection stored in the URL. Conversion ships in Phase 2 (see ADR-0003).